



Commercial Partnerships

iSonea's commercial discussions will commence now

- iSonea's proprietary Acoustic Respiratory Measurement (ARM™) technology, which underpins all our products, has been clinically validated in independent clinical studies over the years using PulmoTrack™ and WHolter™ products. The outcomes of these studies have been successful and have been published in respected medical journals.
- Thus iSonea already has a strong and attractive portfolio to complement other product offerings in the health sector.
- This same proprietary ARM technology is also employed in the AirSonea® asthma wheeze monitor and app. AirSonea is a wireless monitoring device for use in the home. The device connects via Bluetooth to smartphones with AirSonea's Asthma Management App to detect and measure wheeze.
- The AirSonea device and app enables collaborative input from potential industry partners into our follow-up trial that focuses on the efficacy of AirSonea of managing asthma in children during and after an acute asthma attack.

AirSonea offers the pharmaceutical industry the opportunity to objectively evaluate different treatment modalities


- Wheezing is a common problem in infants and preschool children and may be caused by a variety of factors. The major problem facing companies wishing to develop and evaluate treatments of wheezing disorder in preschool children is the lack of any objective measurement of the frequency and severity of airway obstruction.
- This subjectivity presents a challenge to pharmaceutical companies trying to develop asthma treatments for preschool children.
- The potential importance of a wheeze detector to the pharmaceutical industry, is demonstrated in “Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants” by Blanken et al and the corresponding editorial by Robert F. Lemanske Jr., MD published in the New England Journal of Medicine.

*“A major concern with using wheezing to define an illness is the subjectivity involved in assessing this symptom in terms of caregiver recognition, agreement between parental and physician assessment, and recognition of the degree of severity that portends subsequent administration of systemic glucocorticoids or hospitalisation.”**

- AirSonea provides the opportunity for objectively evaluating different treatment modalities for wheezy preschool children in whom current management is largely based on subjective observation.
- Therefore, in addition to its domestic and consumer applications, AirSonea is also an enabling technology for pharmaceutical companies to progress their own respiratory treatments. This presents substantial areas for commercial collaboration.

**N Engl J Med 368:19 9th May 2013*

iSonea brings Digital Health Capabilities and Proprietary Technology to the World's Largest Healthcare Companies



Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.